Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Loganathan, T.; Jit, M.; Hutubessy, R.; Ng, C.W.; Lee, W.S.; Verguet, S. (2016)
Publisher: Wiley
Languages: English
Types: Article
To evaluate rotavirus vaccination in Malaysia from the household's perspective. The ECEA framework quantifies the broader value of universal vaccination starting with non-health benefits such as financial risk protection and equity. These dimensions better enable decision-makers to evaluate policy on the public finance of health programs. We use an extended cost-effectiveness analysis (ECEA). The incidence, health service utilization and household expenditure related to rotavirus gastroenteritis according to national income quintiles were obtained from local data sources. Multiple birth cohorts were distributed into income quintiles and followed from birth over the first five years of life in a multi-cohort, static model. We found that the rich pay more out-of-pocket (OOP) than the poor, as the rich use more expensive private care. OOP payments among the poorest although small, are high as a proportion of household income. Rotavirus vaccination results in substantial reduction in rotavirus episodes and expenditure, and provides financial risk protection to all income groups. Poverty reduction benefits are concentrated amongst the poorest two income quintiles. We propose that universal vaccination complements health financing reforms in strengthening UHC. ECEA provides an important tool to understand the implications of vaccination for UHC, beyond traditional considerations of economic efficiency. This article is protected by copyright. All rights reserved.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • and Sweden. Washington, DC: Results for Development Institute (R4D), 2011. 5. Ministry of Health Malaysia. Recent illness/injury, health seeking behaviour and out-of-pocket
    • ehealth care expenditure. Malaysia: Institute of Public Health, Ministry of Health, 1996. 6. lJaafar S, Noh KM, Muttalib KA, Othman N, Healy J. Malaysia Health System Review. Geneva,
    • cand Policies), 2013 Contract No.: No.1 7. iLoganathan T, Lee W-S, Lee K-F, Jit M, Ng C-W. Household Catastrophic Healthcare Expenditure and
    • t2015;10(5):e0125878. 8. Xu K, Evans DB, Carrin G, Aguilar-Rivera AM, Musgrove P, Evans T. Protecting households from
    • catastrophic health spending. Health Affairs. 2007;26(4):972-83. 9. Kruk ME, Goldmann E, Galea S. Borrowing and selling to pay for health care in low-and middle-
    • income countries. Health Affairs. 2009;28(4):1056-66.
    • A 10. Berki SE. A look at catastrophic medical expenses and the poor. Health Affairs. 1986;5(4):138-45. 11. Xu K, Saksena P, Jowett M, Indikadahena C, Kutzin J, Evans DB. Exploring the thresholds of health
    • 2010 Contract No.: Background Paper 19.
    • d 12. Wagstaff A. Measuring financial protection in health. Washington DC: World Bank, 2008. 13. O'Donnell OA, Wagstaff A. Analyzing health equity using household survey data: A guide to
    • techniques and their implementation. Washington DC: The World Bank 2008. 14. Wagstaff A, Van Doorslaer E. Catastrophe and impoverishment in paying for health care: with
    • applications to Vietnam 1993-1998. Health Economics. 2003;12(11):921-33. 15. Van Doorslaer E, O'Donnell O, Rannan-Eliya RP, Somanathan A, Adhikari SR, Garg CC, et al. Effect of
    • ppayments for health care on poverty estimates in 11 countries in Asia: An analysis of household
    • survey data. The Lancet. 2006;368(9544):1357-64. 16. eFlores G, Krishnakumar J, O'Donnell O, Van Doorslaer E. Coping with health-care costs: Implications
    • c 17. Xu K, Evans DB, Kadama P, Nabyonga J, Ogwal PO, Nabukhonzo P, et al. Understanding the impact
    • & Medicine 2006;62(4):866-76. 18. Alam K, Mahal A. Economic impacts of health shocks on households in low and middle income
    • countries: A review of the literature. Global Health. 2014;10:21. 19. Saksena P, Hsu J, Evans D. Financial risk protection and universal health coverage: Evidence and
    • emeasurement challenges. PLoS Medicine. 2014;11(9):e1001701. 20. lParashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by
    • rotavirus disease in children. Emerging Infectious Diseases. 2003;9(5):565-72. 21. cParashar UD, Burton A, Lanata C, Boschi-Pinto C, Shibuya K, Steele D, et al. Global mortality
    • iassociated with rotavirus disease among children in 2004. Journal of Infectious Diseases.
    • 2009;200(Supplement 1):S9-S15.
    • t 22. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD. 2008 estimate of worldwide
    • rotavirus-associated mortality in children younger than 5 years before the introduction of universal
    • Diseases. 2012;12(2):136-41. 23. Bilcke J, Van Damme P, Van Ranst M, Hens N, Aerts M, Beutels P. Estimating the incidence of
    • 2009;4(6):e6060. 24. World Health Organization. Rotavirus vaccines: WHO position paper January 2013. Geneva,
    • Switzerland: World Health Organization,, 2013 Contract No.: 88.
    • d 25. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and
    • Medicine. 2006;354(1):11-22. 26. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and
    • efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New England Journal
    • of Medicine. 2006;354(1):23-33. 27. pPatel MM, Glass R, Desai R, Tate JE, Parashar UD. Fulfilling the promise of rotavirus vaccines: How
    • far have we come since licensure? The Lancet Infectious Diseases. 2012;12(7):561-70. 28. eYen C, Tate JE, Hyde TB, Cortese MM, Lopman BA, Jiang B, et al. Rotavirus vaccines: Current status
    • and future considerations. Human Vaccines & Immunotherapeutics. 2014;10(6):1-13. 29. Atherly DE, Lewis KD, Tate J, Parashar UD, Rheingans RD. Projected health and economic impact of
    • rotavirus vaccination in GAVI-eligible countries: 2011-2030. Vaccine. 2012;30 Suppl 1:A7-14. 30. Tu HA, Woerdenbag HJ, Kane S, Rozenbaum MH, Li SC, Postma MJ. Economic evaluations of
    • Vaccines. 2011;10(7):1037-51. 31. Kim S-Y, Sweet S, Slichter D, Goldie SJ. Health and economic impact of rotavirus vaccination in GAVI-
    • eligible countries. BMC Public Health. 2010;10(1):1-24. 32. eNelson EAS, de Quadros CA, Santosham M, Parashar UD, Steele AD. Overcoming perceptions of
    • 2013;9(11):2418-26. 33. cKaddar M, Schmitt S, Makinen M, Milstien J. Global support for new vaccine implementation in
    • imiddle-income countries. Vaccine. 2013;31(S):B81-B96. 34. United Nations. Transforming our World: The 2030 Agenda for Sustainable Development. Document
    • tNo. A/RES/70/1. New York, NY: Division for Sustainable Development, Department of Economics
    • and Social Affairs, United Nations, 2015.
    • r 35. Verguet S, Laxminarayan R, Jamison DT. Universal public finance of tuberculosis treatment in India:
    • An extended cost-effectiveness analysis. Health Economics. 2015;24(3):318-32. 36. Jit M, Bilcke J, Mangen MJ, Salo H, Melliez H, Edmunds WJ, et al. The cost-effectiveness of rotavirus
    • 2009;27(44):6121-8. 37. Jit M, Yuzbashyan R, Sahakyan G, Avagyan T, Mosina L. The cost-effectiveness of rotavirus
    • vaccination in Armenia. Vaccine. 2011;29(48):9104-11.
    • d 38. Postma MJ, Jit M, Rozenbaum MH, Standaert B, Tu H-A, Hutubessy RC. Comparative review of three
    • eapproach applied to various regions in the world. BMC Medicine. 2011;9(1):84. 39. Diphteria, tetanus and pertussis (DTP3), Data by Country, Malaysia [Internet]. Global Health
    • Observatory Data Repository. 2013 [cited 6th April 2015]. 40. Child mortality levels. Probability of dying per 1,000 live births, Data by country, Malaysia [Internet].
    • pGlobal Health Observatory Data Repository. 2013 [cited 8th February 2015]. Available from:
    • http://apps.who.int/gho/data/node.main.ChildMort-2?lang=en. 41. eStrategic Advisory Group of Experts. Meeting of the immunization Strategic Advisory Group of
    • Experts April 2009, conclusions and recommendations. Weekly Epidemiological Record.
    • c 42. Walker DG, Hutubessy R, Beutels P. WHO Guide for standardisation of economic evaluations of
    • immunization programmes. Vaccine. 2010;28(11):2356-9.
    • c 43. Ministry of Health Malaysia. The National Health and Morbidity Survey 2011. Malaysia: Institute for
    • Public Health, Ministry of Health, 2011. 44. Loganathan T, Ng CW, Lee WS, Jit M. The hidden health and economic burden of rotavirus
    • eJournal 2016. 45. lRussell S. The economic burden of illness for households in developing countries: A review of
    • i2004;71(Supplement 2):147-55. 46. Bernstein DI. Rotavirus overview. The Pediatric Infectious Disease Journal. 2009;28(3):S50-S3.
    • t 47. Department of Statistics Malaysia. Household income and basic amenities survey report 2009.
    • Malaysia: Department of Statistics, 2009.
    • r 48. Nishtar S. The mixed health systems syndrome. Bulletin of the World Health Organization.
    • 2010;88(1):66-73. 49. Chee HL, Barraclough S, editors. Health care in Malaysia: The dynamics of provision, financing and
    • access. USA and Canada: Routledge 2007. 50. Malaysian National Health Accounts, Health Expenditure Report 1997-2012: Ministry of Health,
    • Malaysia; 2014. 51. Somkotra T, Lagrada LP. Which households are at risk of catastrophic health spending: Experience in
    • Thailand after universal coverage. Health Affairs. 2009;28(3):w467-w78. 52. Moreno-Serra R, Millett C, Smith PC. Towards improved measurement of financial protection in
    • health. PLoS Medicine. 2011;8(9):1166. 53. Ministry of Health Malaysia. Load of illness: Acute diarrhoeal illness. Malaysia: Institute for Public
    • Health, Ministry of Health, 2006. 54. World Bank. World Development Report 1993: Investing in health. New York, NY: Oxford University
    • pPress, 1993 0004-5608. 55. Bärnighausen T, Berkley S, Bhutta Z, Bishai DM, Black MM, Bloom DE, et al. Reassessing the value of
    • evaccines. The Lancet Global Health. 2014;2(5):e251-e2. 56. Bärnighausen T, Bloom DE, Cafiero-Fonseca ET, O'Brien JC. Valuing vaccination. Proceedings of the
    • National Academy of Sciences. 2014;111(34):12313-9.
    • c 57. Jit M, Hutubessy R, Png ME, Sundaram N, Audimulam J, Salim S, et al. The broader economic impact
    • of vaccination: Reviewing and appraising the strength of evidence. BMC Medicine. 2015;13(1):209.
    • c 58. Country introductions of rotavirus vaccine [Internet]. PATH. 2016 [cited 7 January 2016 ]. Available
    • Meedicine, University of Malaya, 50603 Kuala Lumpur, Malaysia. Fax +603 7967 4975, Phone +603 7967
    • 379l7,Email
  • Discovered through pilot similarity algorithms. Send us your feedback.

Share - Bookmark

Cite this article